OnKure Therapeutics, Inc.
OKURDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
OKUR Earnings Report
EPS Est: $-0.58 | FQ end 2026-06
How OKUR's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OKI-179 + binimetinib | Phase 2 | RAS Mutation | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in OnKure Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in OnKure Therapeutics, Inc.'s (OKUR) pipeline across Phase 2. Its lead program is OKI-179 + binimetinib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OnKure Therapeutics, Inc.'s next FDA catalyst?→
OnKure Therapeutics, Inc.'s (OKUR) next tracked catalyst is a Offering expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OKUR biotech catalysts?→
Add OKUR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OnKure Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.